ReviewOpen veterinary journal2025
Antioxidant activity, antibacterial behavior, and anticancer impact of Egyptian propolis.
Review in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Redox-Regulating Propolis- and Honey-Containing Hydrogels in Osteoarthritis.Antioxidants (Basel, Switzerland) · 2026Review
- Potential Efficacy of Propolis in TreatingNutrients · 2025Review
- Oxidative Stress and Inflammation: Drivers of Tumorigenesis and Therapeutic Opportunities.Antioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Propolis, a resinous substance produced by bees, exhibits significant phytochemical and biological properties, which have been explored for various therapeutic applications. Aim: This study investigates the phytochemical composition, antioxidant activity, antibacterial efficacy, and anticancer potential of ethanolic extracts from three propolis samples (P1, P2, and P3). Methods: Phytochemical screening was conducted to determine the presence of bioactive compounds, such as ascorbic acid, saponins, and tannins. Antioxidant activity was evaluated using the phosphomolybdate (PMA) and ferric reducing power (FRP) assays. The antibacterial efficacy against Results: Phytochemical screening revealed considerable quantities of ascorbic acid, saponins, and tannins in the propolis samples. The P1 sample exhibited the most substantial antioxidant activity, with FRP values at 62.9 mg/g DM and PMA content at 20.7 mg/g DM. In antibacterial assays, P1 demonstrated the highest inhibitory zones at the maximum concentration (400 mg/ml), outperforming standard antibiotic treatments. In cytotoxicity and anticancer assays, P1 preserved the highest percentage of RBCs from hemolysis and showed marked anticancer activity, with the lowest cell viability observed at 3.9 µg/ml. Gene expression analysis revealed significant upregulation of immune response genes, particularly in MDA and HepG2 cell lines upon P1 treatment. Conclusion: This study underscores the potent antioxidant, antibacterial, and anticancer properties of propolis, highlighting its potential as a natural therapeutic agent. The observed activities suggest promising applications for propolis in combating bacterial infections and various cancer types, warranting further exploration into its molecular mechanisms and potential clinical uses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.